Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 284
- Registration Number
- NCT03756298
- Locations
- 🇰🇷
Korea University, Guro hospital, Seoul, Korea, Republic of
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 650
- Registration Number
- NCT03745170
- Locations
- 🇨🇳
The Fifth Medical Center,Chinese PLA General Hospital, Beijing, Beijing, China
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 557
- Registration Number
- NCT03734029
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Jilin Cancer Hospital, Chang chun, Jilin, China
Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma
- Conditions
- Colorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Fujian Cancer Hospital
- Registration Number
- NCT03708536
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT03702985
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 200
- Registration Number
- NCT03684863
A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT03678649
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
- Conditions
- Stomach Neoplasms
- Interventions
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1579
- Registration Number
- NCT03675737
- Locations
- 🇨🇷
CIMCA Centro de Investigacion y Manejo del Cancer ( Site 3001), San Jose, Costa Rica
🇨🇷Policlinico San Bosco ( Site 3002), San Jose, Costa Rica
🇨🇷ICIMED - Instituto de Investigacion en Ciencias Medicas ( Site 3000), San Jose, Costa Rica
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or CancerMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 507
- Registration Number
- NCT03653507
- Locations
- 🇺🇸
Parkland Hospital, Dallas, Texas, United States
🇺🇸University of Kansas Cancer Center and Medical Pavilion, Fairway, Kansas, United States
🇵🇹Site PT35109, Braga, Portugal
SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03645876
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.